V. Kovač, MD, PhD, “Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations”, Radiol Oncol, vol. 48, no. 4, Oct. 2014.